A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2025.07.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von James Fan Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. Hauptthemen laut MEDLINE: Multiple Myeloma, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute, Advancing a Healthier Wisconsin Endowment.
Abstract (Originalsprache)
PURPOSE: We investigated autologous stem cell transplantation (ASCT) barriers in a single-center qualitative study by interviewing patients with multiple myeloma (MM), transplant physicians (TPs), and referring physicians (RPs). METHODS: Patients with MM and referred for ASCT evaluation between January 01, 2021 and December 31, 2022, TPs from 2 Wisconsin transplant centers, and RPs from rural and urban Wisconsin were recruited. Interviews were conducted using a semi-structured interview guide focused on ASCT barriers. Transcripts were double-coded and reviewed. An initial codebook with prespecified themes based on the interview guide was developed and iteratively revised. RESULTS: Eighteen patients, 5 TPs, and 4 RPs were interviewed. Four major ASCT barriers themes were identified across all stakeholders: caregiver support, patient concerns and knowledge, financial toxicity, and logistics. Unique themes included social support by patients and ASCT referral by physicians. Lacking caregiver support was more common among single, childless, and socially/geographically isolated patients. Patients were most concerned about side effects, long hospital stays, and quality of life. Patients used online websites and support groups to gain knowledge and support. While most patients experienced financial toxicity, care costs were rarely discussed. Distance from transplant center, transportation, and care coordination were barriers. Referrals from community oncologists are a major barrier. Patients never seen at a transplant center may have the most barriers. CONCLUSION: This qualitative study of both patients and physicians investigating barriers to access to ASCT in MM, provides a much-needed multistakeholder perspective. Interventional strategies targeting key barriers will be critical in improving ASCT utilization in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
- Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. Electronic address: anitadsouza@mcw.edu.
- Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.
Förderung
- NHLBI NIH HHS
- National Heart Lung and Blood Institute
- Advancing a Healthier Wisconsin Endowment
- American Society of Hematology
Zitieren
APA
Wu, J. F., Akinola, I. M., D'Souza, A., & Cusatis, R. (2026). A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.07.002
Vancouver
Wu JF, Akinola IM, D'Souza A, Cusatis R. A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.07.002
BibTeX
@article{Wu2026,
author = {Wu, James Fan and Akinola, Idayat M and D'Souza, Anita and Cusatis, Rachel},
title = {A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2025.07.002}
}
EUVIMED